Pharmacological inhibition of the transcription factor PU.1 in leukemia
Open accessThe DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and further inhibited PU.1 using either RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we developed specifically to allosterically interfere with PU.1-chromatin binding through interaction with the DNA minor groove that flanks PU.1-binding motifs. These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. shRNA or small-molecule inhibition of PU.1 in AML cells from either PU.1lo mutant mice or human patients with AML-inhibited cell growth and clonogenicity and induced apoptosis. In murine and human AML (xeno)transplantation models, treatment with our PU.1 inhibitors decreased tumor burden and resulted in increased survival. Thus, our study provides proof of concept that PU.1 inhibition has potential as a therapeutic strategy for the treatment of AML and for the development of small-molecule inhibitors of PU.1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A very intriguing new prospect for fast antagonism of PU.1 activity is the discovery of small-molecule inhibitors, some of which are highly potent and specific at blocking PU.1 action in leukemia cells; however, these have not yet been tested for effects on normal T-cell development (89).”
From Mechanisms of Action of Hematopoietic Transcription Factor PU.1 in Initiation of T-Cell Development (2019) · cites this paper as [89]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a luminescence reduction of 11.8 ± 22.3% in the presence of the PU.1-motif intercalator DB2313 (Antony-Debré et al., 2017; Munde et al., 2014; P ≤ 0.0001; Table S5).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Antony-Debré et al., 2017
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 2×
“was performed with gene sets from the Molecular Signatures Database (56, 57) and from the PU.”
MethodGenomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Margolin, A. A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-s1-s7 · Cited by 2,420
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
Margolin, A. A., Nemenman, I. M., Basso, K., Wiggins, C. H., Stolovitzky, G. A., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.7916/d8g15zbp · Cited by 2,246
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532 · cited 1×
“1 is important for myeloid and lymphoid differentiation (13, 14), as well as hematopoietic stem cell (HSC) maintenance (15, 16).”
BackgroundReverse engineering of regulatory networks in human B cells
Basso, K., Margolin, A. A., Stolovitzky, G., Klein, U., Dalla-Favera, R., & Califano, A. (2005) · Nature Genetics · doi:10.1038/ng1532 · Cited by 1,404
Kim, J. H., Lee, S.-R., Li, L.-H., Park, H.-J., Park, J.-H., Lee, K. Y., Kim, M.-K., Shin, B. A., & Choi, S.-Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018556 · Cited by 1,338 · cited 1×
“was linked by a sequence encoding a self-cleaving 2A peptide (53).”
BackgroundTargeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130 · cited 1×
“1 is important for myeloid and lymphoid differentiation (13, 14), as well as hematopoietic stem cell (HSC) maintenance (15, 16).”
Background
Research works printed but not linked: 2
- 10.1128/MCB.13.10.6452 · doi:10.1128/mcb.13.10.6452 · Paper page
- 10.1128/MCB.14.1.373 · doi:10.1128/mcb.14.1.373 · Paper page
Cited by
Items 101–119 of 119
Reversible Small Molecule–Nucleic Acid Interactions
Wilson, W. D., & Paul, A. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781837671328-00477 · Cited by 1
Self-citationBarberio, J., Lash, T. L., Nooka, A. K., Naimi, A. I., Patzer, R. E., & Kim, C. (2024) · Acta Haematologica · doi:10.1159/000539127 · Cited by 1
“Proposed biologic mechanisms in the literature are consistent with these results [18 – 22].”
Rowan, S. C., Bora, S. A., Burman, A., Xie, T., & Chen, P. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0196ro · Cited by 1
Poschmann, J., Liu, J., Bomfim, C. C. B., Mollé, A., Sun, W., Foreman, T. W., Cruesy, C., Pierre, G., Kaushal, D., Libero, G. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.09.675072 · Cited by 1
Biophysical Properties of DNA Minor Groove Binding by Heterocyclic Cations of Varying Structures
Erlitzki, N. (2022) · Digital Archive @ GSU · doi:10.57709/14344822
Ha, V. L. (2022) · Digital Archive @ GSU · doi:10.57709/20511045
Transcriptional circuit dynamics in HSPCs
Tatsumi, G., & Steidl, U. G. (2021) · Blood · doi:10.1182/blood.2021012452
“UCB expansion technologies as reported here and by others(7) may provide a paradigm-changing opportunity to use smaller and better HLA-matched units for UCBT; they also set a benchmark for the expansion of other important UCB populations such as MSCs, NK cells,(8) or T cells.(9,10) Indeed, promising results with genet…”
BackgroundSelf-citationPharmacologic Blockade of a Pioneer Transcription Factor
Čermáková, K., & Hodges, H. C. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-3957
Swann, J. W., Fung, J. H., Chen, Z., Olson, O. C., Collins, A., Lhakhang, T. W., Proven, M. A., Zhang, R., Rabadán, R., & Passegue, E. A. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.05.007 · Cited by 1
Du, J., Manna, A. K., Medina-Serpas, M. A., Hughes, E. P., Bisoma, P., Evason, K. J., Young, A., Wilson, W. D., Brusko, T. M., Farahat, A. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.22.683978
Self-citationCase Report: A novel de novo SPI1 mutation identified in a Chinese patient with agammaglobulinemia
Peng, Q., Deng, M., Zeng, X., Cheng, Q., Xie, M., Li, S., & Lu, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1716208 · Cited by 1
Tu, X., Gomez, H. M., Kim, R., Brown, A. C., de Jong, E., Galvao, I., Faiz, A., Bosco, A., Horvat, J. C., Hansbro, P., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22602359
PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockadePreprint
Yashar, W. M., Pacentine, I. V., Taherinasab, A., Nguyen, T., Worme, S. J., Tsuchiya, M., Lusardi, T. A., Hutchinson, C., Fillmore, T., Posso, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.700677
Natural and Artificial Hematopoietic Cell Reprogramming
Yu, D. H., Liu, W., Liu, F., & Cheng, L. (2026) · Cellular Reprogramming · doi:10.1177/21524971261424117
“These fi ndings offer novel insights into the dosage-sensitive regulation of lymphoid lineage commitment by key TFs (Antony-Debré et al., 2017).”
Ciblage thérapeutique de la protéine CDK6 dans les leucémies aiguës myéloïdes
Brault, L. M. (2022) · theses.fr (ABES) · doi:10.70675/26bca708z5a9az4d80z85bfz9159b330b1e8
Ramani, M., Nguyen, N., Solis, J., Tenen, D. G., & Trinh, B. Q. (2026) · Biology · doi:10.3390/biology15181657
“In AML models, these compounds reduce leukemic growth, impair clonogenicity, and prolong survival in xenograft systems [188].”
Polycomb factor PHF19 affects AML initiation, patient prognosis, and survival
Figueroa, G. P. G., Gutiérrez, A., Blanco, E., Vizán, P., Ballaré, C., Sparavier, A., Tosto, M., Minucci, S., Velten, L., & Croce, L. D. (2026) · Science Advances · doi:10.1126/sciadv.aed6757
“Concomitantly, binding motifs for a series of LSC factors involved in LSC maintenance ( 46 ) and survival were found enriched in regions specifically accessible under the MLL-AF9_Phf19 KO condition, such as the Runx cofactors ( 47 ) and Sfpi1 ( 72 ).”
Metadata
- Authors
- Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., Todorova, T. I., Huang, K., Kumar, A., Farahat, A. A., Bartholdy, B., Narayanagari, S.-R., Chen, J., Ambesi-Impiombato, A., Ferrando, A. A., Mantzaris, I., Gavathiotis, E., Verma, A., Will, B., Boykin, D. W., Wilson, W. D., Poon, G. M. K., & Steidl, U.
- Affiliations
- Georgia State University (US)
- Albert Einstein College of Medicine (US)
- Mansoura University (EG)
- Columbia University (US)
- Corresponding author
- Steidl, Ulrich
- ORCID
- Paul, Ananya
- Mitchell, Kelly
- Kim, Hye Mi
- Carvajal, Luis A.
- Todorova, Tihomira I.
- Huang, Kenneth
- Kumar, Arvind
- Farahat, Abdelbasset A.
- Bartholdy, Boris
- Narayanagari, Swathi-Rao
- Chen, Jiahao
- Ambesi-Impiombato, Alberto
- Ferrando, Adolfo A.
- Mantzaris, Ioannis
- Gavathiotis, Evripidis
- Verma, Amit
- Will, Britta
- Wilson, W. David
- Poon, Gregory M.K.
- Steidl, Ulrich
- Venue
- Journal of Clinical Investigation
- Published
- 2017-10-30
- Volume
- 127
- Issue
- 12
- Pages
- 4297-4313
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5707147
- OpenAlex
- W2766367793
- Cited by
- 120
- References
- 58
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 10 · 2023: 16 · 2022: 19 · 2021: 11 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 2
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Leukemia & Lymphoma Society (6504-17)
- Henry and Marilyn Taub Foundation (Taub Foundation Grants Program for MDS Research)
- National Institutes of Health (R01CA217092)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- PU.1, acute myeloid leukemia, transcription factor inhibition, small molecule inhibitors, allosteric inhibition, DNA minor groove, chromatin binding, RNA interference, apoptosis, therapeutic target
- MeSH terms
- THP-1 Cells, Proto-Oncogene Protein Spi-1, Allosteric Regulation, Animals, Chromatin, Humans, Mice, Transgenic, Pentamidine, Proto-Oncogene Proteins, Leukemia, Myeloid, Acute, Trans-Activators, Apoptosis, Xenograft Model Antitumor Assays, RNA Interference, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.